Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8961374 | PMC |
| http://dx.doi.org/10.1177/10760296221084300 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Glycocalyx disruption, endothelial dysfunction and vascular remodeling as underlying mechanisms and treatment targets of chronic venous disease.
Int Angiol
December 2024
Vascular Surgery Research Laboratories, Division of Vascular and Endovascular Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA -
The glycocalyx is an essential structural and functional component of endothelial cells. Extensive hemodynamic changes cause endothelial glycocalyx disruption and vascular dysfunction, leading to multiple arterial and venous disorders. Chronic venous disease (CVD) is a common disorder of the lower extremities with major health and socio-economic implications, but complex pathophysiology.
View Article and Find Full Text PDFSafety and efficacy of antithrombotics in outpatients with symptomatic COVID-19: A systematic review and meta-analysis.
Curr Probl Cardiol
April 2024
Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan.
Background: Coronavirus disease (COVID-19) is a global health emergency, with well over six hundred million infections and over six million deaths to date. Besides other ramifications, it is also associated with inflammation and an augmented risk of thromboembolic complications. Despite this, the risks and benefits of antithrombotic drugs in patients with mild to moderate COVID-19 have not been well-established and remain controversial.
View Article and Find Full Text PDFISTH guidelines for antithrombotic treatment in COVID-19.
J Thromb Haemost
October 2022
Department of Haematology, Manchester University Hospitals, Manchester, UK.
Antithrombotic agents reduce risk of thromboembolism in severely ill patients. Patients with coronavirus disease 2019 (COVID-19) may realize additional benefits from heparins. Optimal dosing and timing of these treatments and benefits of other antithrombotic agents remain unclear.
View Article and Find Full Text PDFEffect of Sulodexide on Circulating Blood Cells in Patients with Mild COVID-19.
J Clin Med
April 2022
Division of Neurology, Johns Hopkins University, Baltimore, MD 14110, USA.
Background. Despite the fact that COVID-19 usually manifests with severe pneumonia, there is a growing body of evidence that life-threatening multiorgan damage is caused by vascular and hemostatic abnormalities. Since there is no established therapy, assessing antithrombotics is indeed important.
View Article and Find Full Text PDFSulodexide: A Benefit for Cardiovascular Sequelae of Long COVID Patients?
Clin Appl Thromb Hemost
April 2022
Department of Vascular-Endovascular Surgery, CLINEDEM, callejón 5 de mayo y calle 7 No 791, Colonia Comercial, 83449 San Luis Rio Colorado, Sonora, México.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!